REMDESIVIR IN COVID-19 AND EXPERIENCE AT THE NATIONAL RESEARCH CARDIAC SURGERY CENTER: «A CASE-CONTROL» RETROSPECTIVE STUDY
Introduction. The fight against COVID-19 has become a major problem for the whole world and it is necessary to accelerate the development of the strategy as much as possible. Currently, studies are ongoing, but cases of special clinical study of the drug remdesivir have been identified. It was shown that this antiviral drug has a good potential to combat COVID-19 in the short term [6], initiated by several studies by Beigel et al. (ACCT 1) [4], Goldman et al. [13] and Spinner et al. [15], to assess the safety and efficacy of remdesivir in patients with COVID-19 [16].
Aim: evaluation of the effectiveness of remdesivir in hospitalized patients with COVID-19 with a moderate course of the disease.
Materials and мethods: This study is retrospective. The methodology includes a retrospective analysis of the medical history of 295 moderately severe COVID-19 patients with prospective laboratory-confirmed PCR testing for SARS-CoV-2, presence of complicated pneumonia, increased chest imaging. The main group - 164 patients with included remdesivir in the treatment protocol.
The control group consisted of 131 patients who received therapy in accordance with the standard protocol for the treatment of COVID-19. Statistical analysis was performed using STATA/MP software. Normally distributed data and categorical variables are presented as mean standard deviation (mean (SD) and numbers with percentages, respectively. Between-group differences in categorical variables were assessed using a chi-square test. All tests were two-tailed, and a p value < 0.05 was considered statistically significant.
Results. The most end point in our study was the time to achieve/improve clinical status. Remdesivir showed a reduction in mean length of stay in hospital. Our study shows that remdesivir is superior to standard treatment. Also, from the results of our study, a great importance was found in the formation of pulmonary fibrosis in patients treated with remdesivir and in the control group of results with the most frequent formation of fibrosis in the first group of CT scans that found the results of the chest organs after 120–180 days from diseases.
Conclusions. Efficacy of remdesivir in hospitalized adult COVID-19 patients with moderate disease. Outcomes were assessed on three important outcome measures: duration of hospitalization, disease and laboratory tests, and need for mechanical ventilation (ALV). Based on these three criteria, this drug has shown good results in getting COVID-19 by all standards.
Makhabbat S. Bekbossynova1, https://orcid.org/0000-0003-2834-617X
Ainur Т. Tauyekelova1, https://orcid.org/0000-0002-4237-9835
Аliya I. Sailybayeva1, https://orcid.org/0000-0002-1489-3837
Аigerim Т. Раймкулова1, Мarzhan К. Dalbekova1
1 NJSC "National Scientific Cardiac Surgery Center", Astana, Republic of Kazakhstan.
1. Aleissa M., Silverman E., Paredes Acosta L., Nutt C., Richterman A., Marty F. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 // Antimicrob Agents Chemother, 2020. 65(1). 128р.
2. Alejandro Piscoya, Luis F. Ng-Sueng, Angela Parra del Riego, Renato Cerna-Viacava, Vinay Pasupuleti, Yuani M. Roman, Priyaleela Thota, C. Michael White, Adrian V. Hernandez Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. 2020. doi: https://doi.org/10.1371/journal.pone.0243705
3. Ali K., Azher T., Baqi M., Binnie A., Borgia S., Carrier F.M., Cavayas Y.A., Chagnon N., Cheng M.P., Conly J., Costiniuk C., Daley P., Daneman N. et al. Canadian Treatments for COVID-19 (CATCO); Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial // CMAJ. 2022 Feb 22;194(7):E242-E251. doi: 10.1503/cmaj.211698. Epub 2022 Jan 19. PMID: 35045989; PMCID: PMC8863204.
4. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C. Remdesivir for the Treatment of Covid-19 - Preliminary Report // N Eng J Med, 2020. May 20. pmid:32445440
5. Cecconi M., Piovani D., Brunetta E. et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy // J Clin Med Res. 2020. 9(5):1548. https://doi.org/10.3390/jcm9051548.
6. Chen R., Sang L., Jiang M. et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China // J Allergy Clin Immunol. 2020. 146:89. https://doi.org/10.1016/j.jaci.2020.05.003.
7. Chibane S., Gibeau G., Poulin F. et al. Hyperacute multi-organ thromboembolic storm in COVID-19: a case report // J Thromb Thrombolysis. 2020. https://doi.org/10.1007/s11239-020-02173-w.
8. Cummings M.J., Baldwin M.R., Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020. 395(10239):1763-1770. https://doi.org/10.1016/S0140-6736(20)31189-2.
9. Dezza F.C., Oliva A., Mauro V., Romani F.E., Aronica R., et al. Real-life use of remdesivir-containing regimens in COVID-19: a retrospective case-control study // Infez Med. 2022 Jun 1;30(2):211-222. doi: 10.53854/liim-3002-6. PMID: 35693052; PMCID: PMC9177180.
10. Ferner R.E., Aronson J.K. Remdesivir in covid-19 // BMJ. 2020. 369: m1610 doi:10.1136/bmj.m1610 (18)
11. Food and Drug Administration. FDA approves first treatment for COVID-19. October 22, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (Accessed on November 08, 2020).
12. Garibaldi B.T., Wang K., Robinson M.L., Zeger S.L., Bandeen-Roche K., Wang M.C., Alexander G.C., Gupta A., Bollinger R., Xu Y. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19 // JAMA Netw Open. 2021 Mar 1;4(3):e213071. doi: 10.1001/jamanetworkopen.2021.3071. PMID: 33760094; PMCID: PMC7991975.
13. Goldman J.D., Lye D.C.B., Hui D.S., Marks K.M, Bruno R., Montejano R., Spinner C.D., Galli M., Ahn M.Y., Nahass R.G., Chen Y.S. et al. GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 // N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27. PMID: 32459919; PMCID: PMC7377062.
14. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 // N Engl J Med. [Epub ahead of print] 2020 Apr 10. pmid:32275812
15. Guan W.-J., Ni Z.-Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N Engl J Med. 2020. 382:1708. https://doi.org/10.1056/NEJMoa2002032.
16. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020. 395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
17. Hu L., Chen S., Fu Y. et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China // Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa539.
18. Identifier NCT04280705, Adaptive COVID-19 Treatment Trial (ACTT); 2020 February https://clinicaltrials.gov/ct2/show/record/NCT04280705?term=NCT04280705&draw=2&rank=1&view=record. (Accessed May 11 2020).
19. Lin H., Cho S., Meyyur Aravamudan V., Sanda H., Palraj R., Molton J., Venkatachalam I. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence // Infection, 2021. 49(3), pp.401-410.
20. Lin H.X.J., Cho S., Meyyur Aravamudan V., Sanda H.Y., Palraj R., Molton J.S., Venkatachalam I. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence // Infection. 2021 Jun;49(3):401-410. doi: 10.1007/s15010-020-01557-7. Epub 2021 Jan 2. PMID: 33389708; PMCID: PMC7778417.
21. Ma A., Cheng J., Yang J., Dong M., Liao X., Kang Y. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients // Crit Care. 2020. 24(1):288. https://doi.org/10.1186/s13054-020-03007-0.
22. National Institute of Allergy and Infectious Diseases. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. (29 April 2020). (Accessed at www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 on 2 February 2021).
23. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021. (Accessed at www.covid19treatmentguidelines.nih.gov on 2 February 2021).
24. Pavoni V., Gianesello L., Pazzi M., Stera C., Meconi T., Frigieri F.C. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia // J Thromb Thrombolysis. 2020. https://doi.org/10.1007/s11239-020-02130-7.
25. Pya Yu., Bekbossynova M., Gaipov A., Lesbekov T., Kapyshev T., Kuanyshbek A., Tauekelova A., Litvinova L., Sailybayeva A., Vakhrushev I., Sarria-Santamera A. Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan 2021. https://doi.org/10.1371/journal.pone.0261272
26. Shang W., Dong J., Ren Y., et al. The value of clinical parameters in predicting the severity of COVID-19 // J Med Virol. 2020. https://doi.org/10.1002/jmv.26031.
27. Spiezia L., Boscolo A., Poletto F. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure // Thromb Haemost. 2020. 120(6):998-1000. https://doi.org/10.1055/s-0040-1710018.
28. Spinner C.D., Gottlieb R.L., Criner G.J., Arribas López J.R., Cattelan A.M., Soriano Viladomiu A., Ogbuagu O., Malhotra P., Mullane K.M. et al. GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial // JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. PMID: 32821939; PMCID: PMC7442954.
29. Wang Y., Zhang D., Du G., Zhao J., Jin Y., Fu S. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial // Lancet. 2020. 395: 1569–78. 10.1016/S0140-6736(20)31022-9 pmid:32423584
30. Williamson B.N., Feldmann F., Schwarz B., Meade-White K., Porter D.P., Schulz J., van Doremalen N., Leighton I., et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 // Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9. PMID: 32516797; PMCID: PMC7486271
31. Yaghi S., Ishida K. et al. SARS-CoV-2 and stroke in a New York healthcare system // Stroke. 2020. 51(7): 2002-2011. https://doi.org/10.1161/STROKEAHA.120.030335.
32. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020. 395:1054. https://doi.org/10.1016/S0140-6736(20)30566-3.
Number of Views: 72
Category of articles:
COVID-19 - Topical Subject
Bibliography link
Bekbossynova M.S., Tauyekelova A.Т., Sailybayeva А.I., Raimkulova A.T. Dalbekova М.К. Remdesivir in COVID-19 and experience at the National Research Cardiac Surgery Center: «A Case-control» retrospective study // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 2, pp. 7-15. doi 10.34689/SH.2023.25.2.001Related publications:
IMMUNOLOGICAL CHANGES IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2
EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
APPLICATION OF ARTIFICIAL INTELLIGENCE IN COMBATING THE COVID-19 PANDEMIC: CURRENT TRENDS AND PROSPECTS. REVIEW
CONSEQUENCES OF THE CORONAVIRUS INFECTION: THE POST-COVID SYNDROME AND MENTAL MANIFESTATIONS. LITERATURE REVIEW
FEATURES OF THE SICKNESS BEHAVIOR OF ARTERIAL HYPERTENSION AND OBESITY DURING THE PANDEMIC OF COVID-19 CORONAVIRUS. REVIEW